ANIMALCARE GROUP PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 224 GBX | +3.23% |
|
+3.23% | +31.76% |
| 04-15 | Transcript : Animalcare Group plc, 2023 Earnings Call, Apr 15, 2024 | |
| 04-11 | Animalcare to sell 33% stake in STEM Animal Health to Dechra | AN |
| Sales 2023 | 74.35M 93.08M 7.44B | Sales 2024 * | 74.85M 93.7M 7.48B | Capitalization | 130M 163M 13.04B |
|---|---|---|---|---|---|
| Net income 2023 | 1M 1.25M 100M | Net income 2024 * | 28M 35.05M 2.8B | EV / Sales 2023 | 1.37 x |
| Net Debt 2023 * | 1.2M 1.5M 120M | Net cash position 2024 * | 27.1M 33.93M 2.71B | EV / Sales 2024 * | 1.38 x |
| P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 220 |
| Yield 2023 * |
2.03% | Yield 2024 * |
2.3% | Free-Float | 64.4% |
More Fundamentals
* Assessed data
More news
Latest transcript on Animalcare Group plc
More press releases
| 1 day | +3.23% | ||
| 1 week | +3.23% | ||
| Current month | +6.67% | ||
| 1 month | +5.66% | ||
| 3 months | +26.20% | ||
| 6 months | +29.86% | ||
| Current year | +31.76% |
1 week
214.00
224.00
1 month
204.00224.00
Current year
165.00230.00
1 year
160.00230.00
3 years
145.00430.00
5 years
132.06430.00
10 years
112.00430.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jennifer Winter
CEO | Chief Executive Officer | 64 | 02/08/18 |
| Director of Finance/CFO | 48 | 31/05/12 | |
| Human Resources Officer | - | 30/11/10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 59 | 12/07/17 | |
Marie Metayer
BRD | Director/Board Member | 64 | 02/05/22 |
Edwin Torr
BRD | Director/Board Member | 63 | 12/07/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 224 | +3.23% | 9 632 |
| 26/04/24 | 217 | 0.00% | 43,842 |
| 25/04/24 | 217 | 0.00% | 10,188 |
| 24/04/24 | 217 | 0.00% | 13,944 |
| 23/04/24 | 217 | 0.00% | 69,209 |
Delayed Quote London S.E., April 29, 2024 at 10:01 am
More quotes
Animalcare Group plc is a United Kingdom-based international veterinary sales and marketing company. The Company is focused on bringing products to market through its own development pipeline, partnerships and through acquisitions. The Company develops and commercializes prescription and over-the-counter pharmaceutical products that improve animal health and wellbeing. These are developed in-house, acquired from other companies or in-licensed from its partners. The Company manages an international supply chain, including specialist veterinary wholesalers and distributors. It partners with companies to commercialize products across Europe. The Company operates in three categories within the veterinary market: companion animals, equine and other, and production animals. Its product pipeline is Daxocox, which is a differentiated COX-2 inhibitor for the treatment of chronic pain in dogs. The Company operates in seven countries and exports to about 40 countries in Europe and worldwide.
Sector
Pharmaceuticals
Calendar
19/06/2024
- Final dividend
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.17
GBP
Average target price
2.935
GBP
Spread / Average Target
+35.25%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +31.76% | 162M | |
| -19.73% | 72.39B | |
| -11.01% | 6.54B | |
| +15.88% | 3.43B | |
| -2.09% | 3.12B | |
| +1.18% | 1.4B | |
| -17.27% | 1.34B | |
| -3.91% | 1.26B | |
| -28.16% | 1.2B | |
| -14.67% | 1.12B |
- Stock Market
- Equities
- ANCR Stock
